PT-141 was derived from Melanotan II research — but they have different receptor selectivity, different regulatory status, and different optimal research applications.
Melanotan II is the original melanocortin research peptide — non-selective, activates MC1R (tanning), MC3R, and MC4R (sexual function and appetite). PT-141 (bremelanotide) is the refined successor — more selective for MC3R and MC4R, drops the tanning effect, carries FDA approval for hypoactive sexual desire disorder, and has a better-characterized safety profile. If the research application is sexual function, PT-141 is the more defensible choice. If tanning or the broader melanocortin profile is relevant, MT-II is the only option — PT-141 won't produce pigmentation.
Melanotan II was developed at the University of Arizona in the 1980s as a potential sunless tanning agent. During clinical trials in the 1990s, researchers noticed an unexpected side effect: male subjects were experiencing penile erections. Rather than treating this as a problem, the research team recognized it as a novel pharmacological mechanism — central melanocortin receptor activation for sexual function — that was mechanistically distinct from anything then available.
This observation launched a second research program to develop a more selective compound that retained the sexual function effects while minimizing the tanning and other off-target effects. That work produced bremelanotide (PT-141), which went through clinical trials and received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Melanotan II itself was never advanced to approval — its non-selective receptor profile and the safety concerns around mole darkening made the regulatory path harder than for the more targeted PT-141.
The FDA approval of PT-141 for sexual dysfunction is the strongest possible validation of the underlying melanocortin mechanism that MT-II pioneered. The mechanism works — the approval confirms that. The question for researchers is which compound's profile fits their specific application.
| Factor | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Receptor profile | MC1R, MC3R, MC4R | MC3R, MC4R (primarily) |
| Tanning / pigmentation | Yes — primary original application | Minimal to none |
| Sexual function effect | Yes — MC4R | Yes — primary application |
| Appetite suppression | Yes — notable | Mild |
| Molecular structure | Cyclic heptapeptide | Cyclic heptapeptide (modified) |
| Half-life | ~1 hour (SubQ) | ~2.7 hours (SubQ) |
| Research dose | 500mcg – 1mg | 1.75mg (FDA approved) |
| Nausea frequency | Higher — non-selective activation | ~40% in trials — well-documented |
| Mole darkening risk | Yes — MC1R activation | Minimal (MC1R not primary target) |
| FDA approval | None | Approved 2019 (Vyleesi) |
| Human safety data | Phase 1/2 trials only | Full Phase 3 + post-market data |
| BP elevation risk | Present | Documented — black box consideration |
| Research Goal | Lean Toward | Rationale |
|---|---|---|
| Tanning / photoprotection | Melanotan II | MC1R activation — PT-141 won't produce this |
| Sexual function (male ED) | Either (MT-II has earlier data) | Both activate MC4R; PT-141 has better safety characterization |
| Sexual function (female HSDD) | PT-141 | FDA-approved indication; Phase 3 data in this population |
| Best human safety data | PT-141 | Full clinical development program vs Phase 1/2 for MT-II |
| Appetite / weight research | Melanotan II | More pronounced MC4R appetite suppression at research doses |
| Minimizing mole/nevi risk | PT-141 | MC1R not primary target — lower melanocyte stimulation |
| Longer action duration | PT-141 | ~2.7hr half-life vs ~1hr for MT-II |
COA-verified vendor pricing with promo codes. Tegridy Research currently carries Melanotan II.
View Pricing → Dosage Calculator